Drug Trial Radar · NCT07024641
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Nov 13, 2024
Primary completion
Nov 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- GigaGen, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.
Conditions
- Hepatitis B Virus Infection
Interventions
GIGA-2339Drug
Administered by intravenous infusion
PlaceboDrug
Administered by intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- SAD and MAD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: SAD: Up to Day 105; MAD: Up to Day 245
Locations
20 sites in 5 countries. Site status is shown where the registry gives one.
Grifols Investigative site
Chandler, Arizona · Recruiting
Grifols Investigative site
Huntington Beach, California · Recruiting
Grifols Investigative site
Lake Forest, California · Recruiting
Grifols Investigative site
Long Beach, California · Recruiting
Grifols Investigative site
Oakland, California · Suspended
Grifols Investigative Site
Peachtree Corners, Georgia · Recruiting
Grifols Investigative Site
Iowa City, Iowa · Recruiting
Grifols Investigative Site
Lenexa, Kansas · Recruiting
Grifols Investigative site
Baltimore, Maryland · Recruiting
Grifols Investigative site
San Antonio, Texas · Recruiting
Grifols Investigative site
Webster, Texas · Recruiting
Grifols Investigative site
Richmond, Virginia · Recruiting
Grifols Investigate Site
Concord, New South Wales, Australia · Recruiting
Grifols Investigative site
Fortitude Valley, Queensland, Australia · Recruiting
Grifols Investigative site
Hong Kong, Hong Kong Island, Hong Kong · Recruiting
Grifols Investigative site
Shatin, New Territories, Hong Kong · Recruiting
Grifols Investigative site
Seogu, Busan, South Korea · Recruiting
Grifols Investigative site
Songpa-dong, Seoul, South Korea · Recruiting
Grifols Investigative site
Sanmin, Kaohsiung, Taiwan · Recruiting
Grifols Investigative site
Zhongzheng, Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.